We previously reported on the partial prevention of experimental shunt-induced pulmonary arterial hypertension (PAH) by the nonselective endothelin (ET) ET-A/ET-B receptor antagonist bosentan. As the ...

VENOUS anastomoses connecting the portal and pulmonary veins have been shown in cirrhotic patients by post-mortem injection, 1 and there has been considerable speculation concerning their possible ...

Among patients with advanced chronic obstructive pulmonary disease (COPD), an arteriovenous (AV) shunt improves physiological parameters such as cardiac output and oxygen delivery but does not have a ...

The characteristics of hepatopulmonary syndrome include an oxygen saturation < 80%, an increased alveolar-arterial gradient (> 15 mm Hg) while breathing room air, portal hypertension with or without ...

Systemic to pulmonary arterial shunts are surgically created connections between the aorta and a pulmonary artery in children with cyanotic congenital heart disease, such as tetralogy of Fallot or ...

A patent foramen ovale has been observed in about 20 per cent of persons surveyed. 5 A similar proportion has been observed in this . . . From the Department of Medicine, Royal Hospital, Sheffield ...

V-Wave has raised $98 million to complete the clinical testing of its implant for severe heart failure and pulmonary arterial hypertension, as well as set up the device for FDA review. The company’s ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...